Nexstim Plc · OMXHEX:NXTMH
Nexstim — FY2021 Earnings Presentation
9 slides from Nexstim's earnings presentation, Feb 28, 2022
Slide 1: Nexstim - Personalized brain diagnostics and therapy
Nexstim - Personalized brain diagnostics and therapy Mikko Karvinen| CEO| Nexstim Plc Joonas Juokslahti| CFO| Nexstim Plc H2 2021 & FY 2021 Financial Results Webinar, 28 Feb 2022 Nexstim Oyj
Slide 2: Important Information
Important Information This document and the information contained herein are being presented by Nexstim Oyj other than the date of this presentation. Nothing contained herein is, or should be relied upon (“Nexstim” or the “Company”). In connection with any presentation or review of this document, as
Slide 3: Nexstim Story
Nexstim Story Nexstim is a Finnish, globally operating medical technology company. MISSION VISION VALUES We enable personalized and Our innovations create a Science and clinical evidence effective therapies and possibility for a better life. diagnostics for challenging Financial success brain diseas
Slide 4: Megatrends that Support our Growth
Megatrends that Support our Growth Nexstim’s unique proprietary neuronavigated TMS-technology for both diagnostic and therapy applications. • Population aging and a significant decline in the Aging population working-age and able population in Western countries • Brain diseases increase with aging T
Slide 5: Our Business and Products
Our Business and Products Commercial Business System Application Europe United States Status NBS Diagnostics (Navigated Over 200 Pre-surgical CE marked FDA approved Business Brain systems sold mapping Stimulation) FDA approved Depression CE marked with existing NBT® Over 50 reimbursement Therapy (Na
Slide 6: Nexstim Business Summary 2021
Nexstim Business Summary 2021 • Nexstim’s historically best full year measured by net sales, operating result and result for the review period • First positive Result for the Period in H2 2021 in the history of the company • Business has continued to grow fast despite changes in the operating enviro
Slide 7: 2021 Key Financials
2021 Key Financials Key Financials of the Group Total net sales 6.4M€ +56% 1–12/2021 1–12/2020 • NBS net sales 3.7M€ +71% EUR in thousands Change-% 12 months 12 months • NBT net sales 2.7M€ +38% • System sales 3.7M€ +113% Net Sales 6,397.5 4,114.0 55.5 • Recurring Revenue 2.7M€ +13% Gross Margin 5,2
Slide 8: Key Strategic Objectives 2022
Nexstim Key Strategic Objectives 2022 Continued profitable net sales growth, leading into our first operating 1 profit-making financial year, while also minimizing future capital needs Expansion of Nexstim’s network of exclusive neuroscience center 2 partner clinics, especially in the United States
Slide 9: Thank you!
Thank you! Nexstim Oyj Nexstim Plc Public Presentation 9